{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:47:19Z","timestamp":1788353239079,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10792-019-01208-3","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T08:03:23Z","timestamp":1573459403000},"page":"477-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity"],"prefix":"10.1007","volume":"40","author":[{"given":"Amir","family":"Eftekhari Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Hassanpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Mousavi Mirkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Golizade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Reza","family":"Niyousha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"issue":"2","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5\u00a0years of follow-up. Retina 33(2):329\u2013338","journal-title":"Retina"},{"key":"1208_CR2","first-page":"383","volume":"42","author":"TL Terry","year":"1944","unstructured":"Terry TL (1944) Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Trans Am Ophthalmol Soc. 42:383\u2013396","journal-title":"Trans Am Ophthalmol Soc."},{"issue":"2","key":"1208_CR3","first-page":"228","volume":"6","author":"FM Mutlu","year":"2013","unstructured":"Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6(2):228\u2013236","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol (Chicago, Ill 1960) 121(12):1684\u20131694","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"1","key":"1208_CR5","first-page":"155","volume":"27","author":"N Soejima","year":"1976","unstructured":"Soejima N, Takagi I, Takashima Y (1976) Clinical studies on retinopathy of prematurity, severe and rapidly progressive type. Folia Ophthalmol Jpn 27(1):155\u2013161","journal-title":"Folia Ophthalmol Jpn"},{"issue":"7","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/archopht.1987.01060070042025","volume":"105","author":"T Aaberg","year":"1987","unstructured":"Aaberg T, Ben-Sira I, Charles S, Clarkson J, Cohen BZ, Flynn J, Foos R, Garner A, Hirose T, Koerner F, Machemer R (1987) An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol (Chicago, Ill 1960) 105(7):906\u2013912","journal-title":"Arch Ophthalmol (Chicago, Ill 1960)"},{"issue":"7","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123(7):991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1208_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77\u201382","journal-title":"Early Hum Dev"},{"issue":"3","key":"1208_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","author":"J Feng","year":"2017","unstructured":"Feng J, Qian J, Jiang Y et al (2017) Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology 124(3):408\u2013409","journal-title":"Ophthalmology"},{"issue":"4","key":"1208_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 35(4):675\u2013680","journal-title":"Retina."},{"issue":"6","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78(6):340\u2013343","journal-title":"Arq Bras Oftalmol"},{"key":"1208_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaapos.2016.09.012","volume":"20","author":"A Khodabande","year":"2016","unstructured":"Khodabande A, Niyousha MR, Roohipoor R (2016) A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity. J AAPOS 20:490\u2013492","journal-title":"J AAPOS"},{"issue":"4","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1542\/peds.2004-1309","volume":"115","author":"BA Darlow","year":"2005","unstructured":"Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 115(4):990\u2013996","journal-title":"Pediatrics"},{"issue":"11","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/eye.2011.208","volume":"25","author":"SJ Woo","year":"2011","unstructured":"Woo SJ, Park KH, Ahn J et al (2011) A co-twin study of the relative effect of birth weight and gestational age on retinopathy of prematurity. Eye (London) 25(11):1478\u20131483","journal-title":"Eye (London)"},{"issue":"3","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"F193","DOI":"10.1136\/adc.2008.143552","volume":"94","author":"CA Dhaliwal","year":"2009","unstructured":"Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N (2009) Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 94(3):F193\u2013F195","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1208_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","volume":"29","author":"G Sanghi","year":"2009","unstructured":"Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S (2009) Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina 29:1335\u20131339","journal-title":"Retina"},{"key":"1208_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.12659\/MSM.897095","volume":"22","author":"SD Nicoar\u0103","year":"2016","unstructured":"Nicoar\u0103 SD, \u015etef\u0103nu\u0163 AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22:1192\u20131209","journal-title":"Med Sci Monit"},{"issue":"23","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.4103\/0366-6999.194638","volume":"129","author":"Xiu-Juan Li","year":"2016","unstructured":"Li Xiu-Juan, Yang Xiao-Peng, Sun Shuang, Lyu Xiao-Bei, Jia Heng (2016) Intravitreal ranibizumab for aggressive posterior retinopathy of prematurity. Chin Med J (Engl) 129(23):2879\u20132881","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"S-N Chen","year":"2015","unstructured":"Chen S-N, Lian I, Hwang Y-C et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 35(4):667\u2013674","journal-title":"Retina"},{"issue":"7","key":"1208_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MAM Castellanos","year":"2013","unstructured":"Castellanos MAM, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816\u2013819","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1208_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5935\/0004-2749.20170009","volume":"80","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, Ko\u00e7luk Y (2017) The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 80(1):30\u201334","journal-title":"Arq Bras Oftalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-019-01208-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-019-01208-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:15:52Z","timestamp":1604949352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-019-01208-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s10792-019-01208-3","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no grant and no conflict of interest for all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted based on principles of the Declaration of Helsinki. The study protocol was supervised and approved by the Ethical Committee of Tabriz University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The written inform consent was received from all the participants\u2019 legal parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Inform consent"}}]}}